193 related articles for article (PubMed ID: 31719169)
41. Cancer Risks Associated With
Fortuno C; Feng BJ; Carroll C; Innella G; Kohlmann W; Lázaro C; Brunet J; Feliubadaló L; Iglesias S; Menéndez M; Teulé A; Ballinger ML; Thomas DM; Campbell A; Field M; Harris M; Kirk J; Pachter N; Poplawski N; Susman R; Tucker K; Wallis M; Williams R; Cops E; Goldgar D; ; James PA; Spurdle AB
JCO Precis Oncol; 2024 Feb; 8():e2300453. PubMed ID: 38412388
[TBL] [Abstract][Full Text] [Related]
42. Genetic testing in Li-Fraumeni syndrome: uptake and psychosocial consequences.
Lammens CR; Aaronson NK; Wagner A; Sijmons RH; Ausems MG; Vriends AH; Ruijs MW; van Os TA; Spruijt L; Gómez García EB; Kluijt I; Nagtegaal T; Verhoef S; Bleiker EM
J Clin Oncol; 2010 Jun; 28(18):3008-14. PubMed ID: 20479422
[TBL] [Abstract][Full Text] [Related]
43. Genetic counseling can influence the course of a suspected familial cancer syndrome patient: from a case of Li-Fraumeni like syndrome with a germline mutation in the TP53 gene.
Hwang SM; Lee ES; Shin SH; Kong SY
Korean J Lab Med; 2008 Dec; 28(6):493-7. PubMed ID: 19127115
[TBL] [Abstract][Full Text] [Related]
44. Contribution of de novo and mosaic
Renaux-Petel M; Charbonnier F; Théry JC; Fermey P; Lienard G; Bou J; Coutant S; Vezain M; Kasper E; Fourneaux S; Manase S; Blanluet M; Leheup B; Mansuy L; Champigneulle J; Chappé C; Longy M; Sévenet N; Paillerets BB; Guerrini-Rousseau L; Brugières L; Caron O; Sabourin JC; Tournier I; Baert-Desurmont S; Frébourg T; Bougeard G
J Med Genet; 2018 Mar; 55(3):173-180. PubMed ID: 29070607
[TBL] [Abstract][Full Text] [Related]
45. [Germline mutations of TP53 gene among Chinese families with high risk for breast cancer].
Yang X; Hu Z; Wu J; Liu G; Di G; Chen C; Hou Y; Huang X; Liu Z; Shen Z; Shao Z
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2015 Dec; 32(6):761-5. PubMed ID: 26663043
[TBL] [Abstract][Full Text] [Related]
46. Genotype-phenotype correlations among TP53 carriers: Literature review and analysis of probands undergoing multi-gene panel testing and single-gene testing.
Fortuno C; Pesaran T; Mester J; Dolinsky J; Yussuf A; McGoldrick K; James PA; Spurdle AB
Cancer Genet; 2020 Oct; 248-249():11-17. PubMed ID: 32966936
[TBL] [Abstract][Full Text] [Related]
47. Penetrance Estimates Over Time to First and Second Primary Cancer Diagnosis in Families with Li-Fraumeni Syndrome: A Single Institution Perspective.
Shin SJ; Dodd-Eaton EB; Gao F; Bojadzieva J; Chen J; Kong X; Amos CI; Ning J; Strong LC; Wang W
Cancer Res; 2020 Jan; 80(2):347-353. PubMed ID: 31719099
[TBL] [Abstract][Full Text] [Related]
48. Identification of a novel germ-line mutation in the TP53 gene in a Mexican family with Li-Fraumeni syndrome.
Taja-Chayeb L; Vidal-Millán S; Gutiérrez-Hernández O; Trejo-Becerril C; Pérez-Cárdenas E; Chávez-Blanco A; de la Cruz-Hernández E; Dueñas-González A
World J Surg Oncol; 2009 Dec; 7():97. PubMed ID: 20017945
[TBL] [Abstract][Full Text] [Related]
49. Guidelines for the Li-Fraumeni and heritable TP53-related cancer syndromes.
Frebourg T; Bajalica Lagercrantz S; Oliveira C; Magenheim R; Evans DG;
Eur J Hum Genet; 2020 Oct; 28(10):1379-1386. PubMed ID: 32457520
[TBL] [Abstract][Full Text] [Related]
50. Germline TP53 Mutations in Patients With Early-Onset Colorectal Cancer in the Colon Cancer Family Registry.
Yurgelun MB; Masciari S; Joshi VA; Mercado RC; Lindor NM; Gallinger S; Hopper JL; Jenkins MA; Buchanan DD; Newcomb PA; Potter JD; Haile RW; Kucherlapati R; Syngal S;
JAMA Oncol; 2015 May; 1(2):214-21. PubMed ID: 26086041
[TBL] [Abstract][Full Text] [Related]
51. Population-based estimate of the contribution of TP53 mutations to subgroups of early-onset breast cancer: Australian Breast Cancer Family Study.
Mouchawar J; Korch C; Byers T; Pitts TM; Li E; McCredie MR; Giles GG; Hopper JL; Southey MC
Cancer Res; 2010 Jun; 70(12):4795-800. PubMed ID: 20501846
[TBL] [Abstract][Full Text] [Related]
52. Whole-exome analysis of a Li-Fraumeni family trio with a novel TP53 PRD mutation and anticipation profile.
Franceschi S; Spugnesi L; Aretini P; Lessi F; Scarpitta R; Galli A; Congregati C; Caligo MA; Mazzanti CM
Carcinogenesis; 2017 Sep; 38(9):938-943. PubMed ID: 28911001
[TBL] [Abstract][Full Text] [Related]
53. [Li-Fraumeni syndrome - a proposal of complex prevention care for carriers of TP53 mutation with total-body MRI].
Foretová L; Stěrba J; Opletal P; Mach V; Lisý J; Petráková K; Palácová M; Navrátilová M; Gaillyová R; Puchmajerová A; Křepelová A; Macháčková E
Klin Onkol; 2012; 25 Suppl():S49-54. PubMed ID: 22920207
[TBL] [Abstract][Full Text] [Related]
54. TP53 and CDKN1A mutation analysis in families with Li-Fraumeni and Li-Fraumeni like syndromes.
Andrade RC; Dos Santos AC; de Aguirre Neto JC; Nevado J; Lapunzina P; Vargas FR
Fam Cancer; 2017 Apr; 16(2):243-248. PubMed ID: 27714481
[TBL] [Abstract][Full Text] [Related]
55. Rates of Intervention and Cancer Detection on Initial versus Subsequent Whole-body MRI Screening in Li-Fraumeni Syndrome.
Kagami LAT; Du YK; Fernandes CJ; Le AN; Good M; Duvall MM; Baldino SE; Powers J; Zelley K; States LJ; Mathew MC; Katona BW; MacFarland SP; Maxwell KN
Cancer Prev Res (Phila); 2023 Sep; 16(9):507-512. PubMed ID: 37428016
[TBL] [Abstract][Full Text] [Related]
56. Clinical implications of germline mutations in breast cancer: TP53.
Schon K; Tischkowitz M
Breast Cancer Res Treat; 2018 Jan; 167(2):417-423. PubMed ID: 29039119
[TBL] [Abstract][Full Text] [Related]
57. Joint effects of germ-line TP53 mutation, MDM2 SNP309, and gender on cancer risk in family studies of Li-Fraumeni syndrome.
Wu CC; Krahe R; Lozano G; Zhang B; Wilson CD; Jo EJ; Amos CI; Shete S; Strong LC
Hum Genet; 2011 Jun; 129(6):663-73. PubMed ID: 21305319
[TBL] [Abstract][Full Text] [Related]
58. A novel TP53 germline inframe deletion identified in a Spanish series of Li-fraumeni syndrome suspected families.
Llovet P; Illana FJ; Martín-Morales L; de la Hoya M; Garre P; Ibañez-Royo MD; Pérez-Segura P; Caldés T; García-Barberán V
Fam Cancer; 2017 Oct; 16(4):567-575. PubMed ID: 28573494
[TBL] [Abstract][Full Text] [Related]
59. Inherited TP53 Variants and Risk of Prostate Cancer.
Maxwell KN; Cheng HH; Powers J; Gulati R; Ledet EM; Morrison C; Le A; Hausler R; Stopfer J; Hyman S; Kohlmann W; Naumer A; Vagher J; Greenberg SE; Naylor L; Laurino M; Konnick EQ; Shirts BH; AlDubayan SH; Van Allen EM; Nguyen B; Vijai J; Abida W; Carlo MI; Dubard-Gault M; Lee DJ; Maese LD; Mandelker D; Montgomery B; Morris MJ; Nicolosi P; Nussbaum RL; Schwartz LE; Stadler Z; Garber JE; Offit K; Schiffman JD; Nelson PS; Sartor O; Walsh MF; Pritchard CC
Eur Urol; 2022 Mar; 81(3):243-250. PubMed ID: 34863587
[TBL] [Abstract][Full Text] [Related]
60. TP53 germline mutation testing in early-onset breast cancer: findings from a nationwide cohort.
Bakhuizen JJ; Hogervorst FB; Velthuizen ME; Ruijs MW; van Engelen K; van Os TA; Gille JJ; Collée M; van den Ouweland AM; van Asperen CJ; Kets CM; Mensenkamp AR; Leter EM; Blok MJ; de Jong MM; Ausems MG
Fam Cancer; 2019 Apr; 18(2):273-280. PubMed ID: 30607672
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]